Russia will test the 'Sputnik Light' Covid vaccine to take it further

 

 Russia has conducted a clinical trial of a dose of "Sputnik Light" version of its Coronavirus vaccine, officials said Monday, explaining possible "temporary" solutions to help countries with an increase in infection rates.

 

According to official clinical trials, the thin-walled vaccine will be tested’ on 150 people in Moscow and St. Petersburg.

 

So far, more than a million Russians have been rescued’ from the original two-dose version of Sputnik V, named after a Soviet-era satellite that approved the project's geographical significance for Moscow, according to officials. He started the space race.

 

The two-dose vaccine will remain the original version used in Russia, the head of Russia's Sovereign Wealth Fund, Krill Dmitriev, who is in charge of overseas marketing of Sputnik V, said on Monday.

 

However, a food version can be used’ for export.

 

"Sputnik Light" could serve as an effective temporary solution for many countries facing the peak of coronavirus infection, "said Dmitriev, head of the Russian Direct Investment Fund (RDIF). Meeting the costs of the trial, he said.

 

Several governments are considering ways to increase the supply of the COVID-19 vaccine, including delaying the second dose and reducing the size of the dose.

 

The goal is to maximize the number of people receiving at least partial immunity. , Which would reduce the number of potentially serious cases and reduce the burden on health and the health system.

 

The two doses of Sputnik are made’ using different inactive viruses, called vectors, and some Russian manufacturers are looking for a second less stable to produce, which results in the removal of the first component.

 

Last month, Russia shipped 300,000 vials of the Stotinka V vaccine to Argentina, the first major shipment of the vaccine internationally. According to Reuters, the consignment was made’ from only the first ingredient, which is made from this extra batch.

 

President Vladimir Putin has said that one does will provide less protection than two doses but will "still reach 85%".

 

The Jamila Institute, which developed the vaccine, says it is more than 91 percent effective after a two-dose course.

 

According to the Tass News Agency, Alexander Ginsberg, director of the Jamilia Institute, said that after only the first shot of the Sphincton V, the safety immunity lasts for about 3-4 months.